The facts underlying this summary come from an SEC EDGAR Form 8-K filed and published on May 29, 2024. No other source documents are referenced in the available record.
On the advisory side, Goldman Sachs & Co. LLC served as financial advisor to GTCR, the acquirer, in a lead capacity, working alongside Kirkland & Ellis LLP and Cleary Gottlieb Steen & Hamilton LLP, which together provided legal counsel to GTCR. For Surmodics, the target, Jefferies LLC served as financial advisor in a lead role, while Faegre Drinker Biddle & Reath LLP provided legal counsel to the company.
Legal representation breaks down cleanly by side: Kirkland & Ellis LLP and Cleary Gottlieb Steen & Hamilton LLP represented the acquirer, GTCR, while Faegre Drinker Biddle & Reath LLP represented the target, Surmodics.
Beyond the cash consideration and the take-private structure implied by the subtype label, the facts block does not provide further detail on the specific per-share price, financing sources, or any contingent consideration elements that may be part of the agreement.
A number of details are not disclosed in the available record. No expected closing date is given. No information is provided about financing commitments or termination fees. The facts block also does not specify what approvals are outstanding under the pending-regulatory status.